Atai Life Sciences (ATAI) Upgraded to Buy: Here's What You Should Know
TD Cowen Maintains ATAI Life Sciences(ATAI.US) With Buy Rating
Atai Life Sciences CEO Talks Successful Phase 1 Trial of IV Psilocin Formulation – ICYMI | NASDAQ:ATAI, ETR:9VC
Atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference
Atai Life Sciences Co-CEO Says Initial Results From ELE-101 Show Promise in Treating Depression | NASDAQ:ATAI, ETR:9VC
Express News | Cantor Fitzgerald Reiterates Overweight on ATAI Life Sciences
Atai Life Sciences Announces Update on Beckley Psytech's Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, With Initial Results From Phase 1 and First Patients Dosed in Phase 2a
Atai Life Sciences Optimistic as IV Psilocin Shows Promise in Treating Depression in Early Trial | NASDAQ:ATAI, ETR:9VC
Atai Life Sciences Poised for Success With Rigorous Clinical Trials | NASDAQ:ATAI, ETR:9VC
Don't Freak Out. It Isn't the End of the Line for Psychedelic Medicines. -- Barrons.com
Psychedelic Stocks Trip Up After FDA Advisors Reject MDMA For PTSD Treatment
What's Going On With MindMed And Psychedelic Stocks?
FDA advisory group refuses MDMA marketing authorization; psychedelic concept stocks slump.
The independent advisory group of the US FDA voted against the marketing authorization application for the psychiatric drug MDMA, causing a pre-market drop for the hallucinogenic drug developer.
Psychedelic Stocks Fall as FDA Panel Rejects MDMA Therapy
FDA Advisory Panel Fails to Endorse Psychedelic MDMA Therapy for PTSD
Psychedelic Stocks Mixed as FDA Comments on MDMA Therapy
Atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference
ATAI Life Sciences Announces Appointment of Scott Braunstein and Laurent Fischer as Independent Directors >ATAI
Press Release: Atai Life Sciences Strengthens Board With Appointment of Two New Independent Directors
Atai Life Sciences Bolsters Board With Two New Directors | NASDAQ:ATAI, ETR:9VC
No Data